Slone Partners Places New Chief Medical Officer at Clinical Genomics
(PRWEB) November 15, 2016 -- Executive recruitment firm Slone Partners is proud to announce the placement of Dr. Michael Dugan, an esteemed biotechnology leader with extensive clinical experience in both commercial and academic settings, as Chief Medical Officer of Clinical Genomics.
Clinical Genomics is a leading biotechnology company that develops innovative products for colorectal cancer diagnosis. With a broad intellectual property portfolio including more than 20 patents, Clinical Genomics delivers products to improve early cancer detection.
In his new role, Dr. Dugan will lead medical affairs and clinical trials, develop key opinion leader relationships, and build a Scientific Advisory Board. In addition, he will serve as a member of the executive team responsible for establishing business and payer strategies.
“Dr. Dugan’s unique background will further strengthen the leadership team we have in place. He brings years of clinical, commercial and management experience that will contribute to the sustained growth of Clinical Genomics and to the development of clinically actionable, evidence-driven colorectal cancer recurrence monitoring tools,” stated Dr. Lawrence LaPointe, President & CEO of Clinical Genomics. “Our ongoing strategic collaboration with Slone Partners was instrumental in securing Dr. Dugan’s placement and we look forward to a long-term continuing partnership.”
With over 20 years of experience, Dr. Dugan is an acclaimed healthcare leader and clinical operations expert. Prior to joining Clinical Genomics, he served as President & CEO of MCDXI Medical Diagnostics International where he worked with advanced biotechnology companies in oncology and other clinically related applications to bring novel diagnostic tests to market. Before that, Dr. Dugan was the Senior Vice President of Clinical Development and Medical Affairs at Exact Sciences Corporation. He also served as Medical Director at Quest Diagnostics Nichols Institute, Chief Medical Officer at bioTheranostics, VP & Chief Medical Officer at Roche Molecular Systems, Inc., and VP of Pathology Services at Genzyme Genetics.
Dr. Dugan received a Bachelor of Science in Biology from the University of Notre-Dame and a Medical Degree from the University of Arizona College of Medicine.
About Slone Partners
Founded in 2000, Slone Partners is a premier executive search firm that specializes in recruitment for the diagnostics, life sciences, clinical trials, contract research, healthcare information technology and laboratory testing industries with offices in Boston, Washington, D.C. and San Francisco.
For more information on Slone Partners, visit http://www.slonepartners.com.
About Clinical Genomics
Clinical Genomics is a privately held biotechnology company developing innovative products for colorectal cancer (CRC) diagnosis. With a broad intellectual property portfolio consisting of more than 20 patents, Clinical Genomics, via its wholly-owned subsidiary Enterix Inc., currently offers the user-friendly, patient-preferred colorectal cancer screening InSure® FIT™ assay, a fecal immunochemical test that detects blood in the stool. InSure is also marketed as a lab-based test in Australia and other countries (ColoVantage Home). Building on an established history in the field of CRC screening and diagnosis, Clinical Genomics developed a sensitive and specific blood-based circulating tumor DNA (ctDNA) test for colorectal cancer based on methylated DNA from two genes, BCAT1 and IKZF1. The Company plans to make its two-gene test for recurrence monitoring available prior to the end of 2016.
Clinical Genomics has offices and laboratories in Bridgewater and Edison, New Jersey and Sydney, Australia, and operates as a FDA-registered and TGA-licensed manufacturer and a NATA-accredited laboratory.
For more information, please visit http://www.clinicalgenomics.com.
Valerie Lavoie, Slone Partners, http://www.slonepartners.com, +1 646 851 0713, [email protected]
Share this article